Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) saw a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 209 shares, a decline of 78.5% from the May 14th total of 972 shares. Based on an average trading volume of 10,580,690 shares, the days-to-cover ratio is currently 0.0 days.
Enzolytics Price Performance
ENZC stock opened at $0.00 on Wednesday. Enzolytics has a twelve month low of $0.00 and a twelve month high of $0.00.
Enzolytics Company Profile
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Read More
- Five stocks we like better than Enzolytics
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
